BACKGROUND: Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC). PATIENTS AND METHODS: Data from 98 patients with MSCC receiving radiotherapy plus zoledronic acid were matched 1:2 to 196 patients receiving radiotherapy alone for ten potential prognostic factors. Both groups were compared for local control of MSCC within the irradiated region, overall control of MSCC (local and distant MSCC control), and survival. RESULTS: The 1-year local control rates were 90% after radiotherapy plus zoledronic acid and 81%, after radiotherapy alone (p = 0.042). The 1-year overall control rates were 87% and 75%, respectively (p = 0.016), and the 1-year survival rates were 60% and 52%, respectively (p = 0.17). Results were significant in the Cox proportional hazards model regarding local control (p = 0.024) and overall control (p = 0.008). CONCLUSION: According to the results of this study, zoledronic acid was associated with improved control of MSCC in irradiated patients.
BACKGROUND:Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC). PATIENTS AND METHODS: Data from 98 patients with MSCC receiving radiotherapy plus zoledronic acid were matched 1:2 to 196 patients receiving radiotherapy alone for ten potential prognostic factors. Both groups were compared for local control of MSCC within the irradiated region, overall control of MSCC (local and distant MSCC control), and survival. RESULTS: The 1-year local control rates were 90% after radiotherapy plus zoledronic acid and 81%, after radiotherapy alone (p = 0.042). The 1-year overall control rates were 87% and 75%, respectively (p = 0.016), and the 1-year survival rates were 60% and 52%, respectively (p = 0.17). Results were significant in the Cox proportional hazards model regarding local control (p = 0.024) and overall control (p = 0.008). CONCLUSION: According to the results of this study, zoledronic acid was associated with improved control of MSCC in irradiated patients.
Authors: Catherine H Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; Bruce E Hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman Journal: J Clin Oncol Date: 2003-08-15 Impact factor: 44.544
Authors: Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Ming Zheng Journal: J Natl Cancer Inst Date: 2004-06-02 Impact factor: 13.506
Authors: Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen Journal: J Natl Cancer Inst Date: 2002-10-02 Impact factor: 13.506
Authors: Lee S Rosen; David H Gordon; William Dugan; Pierre Major; Peter D Eisenberg; Louise Provencher; Mary Kaminski; Joe Simeone; John Seaman; Bee-Lian Chen; Robert E Coleman Journal: Cancer Date: 2004-01-01 Impact factor: 6.860
Authors: Dirk Rades; Jasmin N Evers; Amira Bajrovic; Theo Veninga; Johann H Karstens; Steven E Schild Journal: Strahlenther Onkol Date: 2014-03-22 Impact factor: 3.621
Authors: H Shibata; S Kato; I Sekine; K Abe; N Araki; H Iguchi; T Izumi; Y Inaba; I Osaka; S Kato; A Kawai; S Kinuya; M Kodaira; E Kobayashi; T Kobayashi; J Sato; N Shinohara; S Takahashi; Y Takamatsu; K Takayama; K Takayama; U Tateishi; H Nagakura; M Hosaka; H Morioka; T Moriya; T Yuasa; T Yurikusa; K Yomiya; M Yoshida Journal: ESMO Open Date: 2016-03-16